ROCKET PHARMACEUTICALS INC (RCKT)
Health Care · gene therapy · NASDAQ
Rocket Pharmaceuticals develops AAV and lentiviral gene therapies for rare genetic and cardiac diseases with a focus on monogenic disorders.
What ROCKET PHARMACEUTICALS INC does
Rocket Pharmaceuticals is a gene therapy company developing advanced therapy medical products (ATMPs) using adeno-associated virus (AAV) and lentiviral vector (LV) technologies to treat rare genetic and cardiac diseases. The company's pipeline includes candidates for conditions such as fanconi anemia, leukocyte adhesion deficiency, lysosomal storage disorders, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, and other rare monogenic disorders. Rocket acquired Renovacor in December 2022 to expand its gene therapy capabilities in cardiac disease.
Themes: ["gene therapy","rare genetic diseases","rare blood disorders","cardiac gene therapy","lysosomal storage disorders","orphan diseases"]
Fundamentals
- Price$4.19 as of 2026-07-09 close
- Market cap$448M as of 2026-07-10
- 1-year return+30.9% as of 2026-07-09 close
- ROE-70.8% as of 2026-07-10
- Debt / equity0.09 as of 2026-07-10
- Beta0.46 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory risk: success in early-stage studies may not translate to later-stage success, and the company may not obtain FDA approval for its product candidates on the anticipated timeline or at all","Capital requirements and funding risk: as a loss-making development-stage biotech company, Rocket anticipates continued operating losses and may need additional capital to fund R&D, potentially limiting its ability to advance programs if funding is unavailable","Manufacturing and commercialization risk: novel gene therapy manufacturing requires significant cGMP infrastructure and expertise, and the company has limited sales and marketing capabilities which it may need to build or partner to commercialize products"]
Competitors & peers
- Bluebird Bio (BLUE)
- Spark Therapeutics (DPST)
- Pfizer (PFE)
- Roche/Genentech
- Sesen Bio (SESN)
- Audentes Therapeutics (acquired by Astellas)
- Ultragenyx Pharmaceutical (RARE)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.